PHI-101 / Pharos iBT - LARVOL DELTA

The third-generation FLT-3 inhibitor, PLM-102, is a promising therapeutic option for venetoclax-resistant AML (AACR 2025) - "Notably, PLM-102 demonstrated the highest tumor growth inhibitory (TGI) efficacy compared with those of other FLT3 inhibitors including tuspetinib, gilteritinib and PHI-101. In conclusion, PLM-102 completely inhibited FLT3 kinase and its downstream signaling including AKT and STAT3, inducing apoptosis in VR AML cells along with significant inhibition of the tumor growth in the VR xenograft mouse model. These findings suggest that PLM-102, a third-generation FLT-3 inhibitor, is a promising candidate for overcoming venetoclax resistance and could serve as a therapeutic option for venetoclax-resistant AML."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • BCL2 • CASP3 • FLT3 • MCL1 • STAT3

Paros I-Bio applies for designation of ’PHI-101’ as orphan drug to the European Medicines Agency…Expanding global target market [Google translation] (Pharos iBio Press Release) - "Pharos iBio...announced on the 28th that it has submitted an application for orphan drug designation (ODD) for PHI-101, a treatment for acute myeloid leukemia (AML), to the European Medicines Agency (EMA). With this ODD application, Pharos iBio plans to expand the global development and early commercialization potential of PHI-101."

Orphan drug • Acute Myelogenous Leukemia

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML (ASH 2024) - P1a/1b | "75% of these patients had received prior FLT3 inhibitors (Gilteritinib (7), Midostaurin (3), Sorafenib (1), HM43239 (1)). The recommended phase 2 dose will be 160 mg once-daily which resulted in Cmax and AUC0-24 plasma concentrations in Phase 1b of 259 ng/ml and 3,920 ng/ml at cycle 1 day 1. Conclusion : Once-daily dosing of single-agent PHI-101 had a distinct tolerability profile and showed excellent anti-tumor activity across FLT3i-pretreated and FLT3i-naïve patients with R/R FLT3 mutant AML."

Clinical • Acute Myelogenous Leukemia • Anemia • Bone Marrow Transplantation • Febrile Neutropenia • Neutropenia • Thrombocytopenia • FLT3

Paros I-Bio announces phase 1 clinical trial results for acute myeloid leukemia treatment [Google translation] (Nate) - P1 | N=42 | NCT04842370 | "Paros I-Bio...announced on the 9th that it had participated in the American Society of Hematology...and presented the comprehensive research results of the phase 1 clinical trial of 'PHI-101'...According to the results of this phase 1 clinical trial, PHI-101 was confirmed to show safety, tolerability, and therapeutic efficacy in patients with AML who are refractory or have relapsed due to resistance to existing approved treatments...According to the results of the phase 1 study, despite the participation of many patients with high levels of severity and difficulty who had received multiple previous treatments, including FLT3 inhibitors, 50% of the evaluable patients showed comprehensive complete response (CCR)...In addition, the overall response rate (ORR), which indicates a decrease or disappearance of tumor size through PHI-101 administration, was 67%....'We plan to enter full-scale procedures for a global Phase 2 clinical trial in 2025.'"

New P2 trial • P1 data • Acute Myelogenous Leukemia

Hanmi Pharmaceutical, ABL, Aptamer, 'Blood Cancer Treatment' Clinical Results Announced at American Society [Google translation] (Chosun Biz) - "Aptamer Science plans to present an abstract of its blood cancer treatment 'AST-202', which it is developing, at this year's conference....This presentation is expected to confirm the pharmacological characteristics of AST-202 and detailed animal experiment data. In the case of Paros I-Bio, the clinical phase 1 results will be presented as a poster this year as the research abstract for the acute myeloid leukemia treatment 'PHI-101' was adopted last year."

Clinical data • Preclinical • Acute Myelogenous Leukemia

Pharos I-Bio, Conditions for Rebound… Possibility of AI New Drug Technology Transfer [Google translation] (Nate) - "Pharos iBio announced on the 12th that it has completed recruiting patients for the phase 1 clinical trial of its acute myeloid leukemia treatment, 'PHI-101-AML', and that it plans to disclose the research results data for all patients who participated in the clinical trial at the American Society of Hematology (ASH) in December....During the IPO process, it was projected that sales of 55.1 billion won and operating profit of 22.9 billion won would be achieved, led by the global technology transfer contract for PHI-101 in 2025."

Enrollment closed • P1 data • Sales projection • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Korean AML drug shows 50% overall complete response rate in P1 trial (Korea Biomedical Review) - P1 | N=42 | NCT04842370 | "Pharos iBio said Wednesday that it would present poster data from the phase 1 clinical trial of PHI-101 for AML at the American Society of Hematology Annual Meeting, ASH 2024....The meeting will present results from the expanded phase 1b study of PHI-101-AML at the recommended expanded dose of 160 mg monotherapy, along with comprehensive results from the final patient recruitment in the phase 1b study. According to Pharos iBio's study abstract, 75 percent of patients in the phase 1b study relapsed or failed after prior FLT3 inhibitor therapy, and 50 percent of evaluable patients achieved a complete response....Pharos iBio plans to complete the phase 1 clinical trial of PHI-101-AML within the year..."

P1 data • Trial completion date • Acute Myelogenous Leukemia

…Pharos I-Bio to complete phase 1 of leukemia treatment within the year… Aiming for early commercialization [Google translation] (Newspim) - "The company plans to complete phase 1 clinical trials within the year, enter phase 2 trials next year, and pursue early commercialization based on the results. As the phase 1 trials have yielded significant results, phase 2 trials are also expected to proceed smoothly."

Commercial • New P2 trial • Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

PHI-101 synergizes with chemotherapy and PARP inhibitors in preclinical models of ovarian cancer (EORTC-NCI-AACR 2024) - P1 | "Niraparib showed different activities: 0.264 μM in the UWB1.89 parental cells and 0.722 μM in the UWB1.289+BRCA1 cells, with synergy confirmed only in the parental UWB1.289 cells.In vivo efficacy of PHI-101 and Olaparib combination therapy was evaluated using a patient-derived xenograft model...The combination efficacy of PHI-101 with Cisplatin or Topotecan was confirmed across four cells, demonstrating synergism...PHI-101 demonstrates a synergistic effect when combined with both platinum-based and non-platinum-based chemotherapy agents as well as PARP inhibitors. These combinations effectively induce cell death, enhancing anti-tumor activity through PARP cleavage and DNA damage in a dose- and time-dependent manner. This indicates that PHI-101 has significant potential as a combination partner to enhance apoptosis and inhibit DNA repair in OC."

Preclinical • Endometrial Cancer • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor • BRCA • BRCA1 • HRD

Pharos I-Bio Releases Data on Combination Therapy for Relapsed and Refractory Ovarian Cancer [Google translation] (Medipana) - "Pharos I-Bio...announced on the 10th that it will present combination therapy data of its recurrent ovarian cancer treatment drug, PHI-101-OC, at the EORTC-NCI-AACR (ENA), an international cancer conference...Pharos I-Bio plans to present combination therapy data of its recurrent ovarian cancer treatment drug, PHI-101-OC, which was selected as the presentation topic at this conference, in a poster presentation....According to the research abstract to be presented at this conference, PHI-101-OC has been confirmed to have a synergistic effect in inhibiting the growth of cancer cells when administered in combination with not only platinum-based chemotherapy, which is the standard first-line treatment for ovarian cancer, but also PARP inhibitors or non-platinum chemotherapy."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

Paros I-Bio, PHI-101 Investigator Clinical Trial Contract for Treatment of Microscopic Residual Disease [Google translation] (Medifonews) - "Paros I-Bio...announced on the 26th of last month that it signed an investigator-led clinical trial contract with ALLG (Australasian Leukaemia and Lymphoma Group), a leukemia and lymphoma specialized clinical research group in Oceania, for 'PHI-101', which is being developed as a treatment for acute myeloid leukemia (AML)....This PHI-101 investigator-initiated clinical trial (clinical trial name: ALLG AMLM26 INTERCEPT) will be conducted simultaneously in hospitals located in Australia, New Zealand, and the United States with the support of ParosiBio and ALLG....The company also plans to use the results of this MRD treatment study as reference material for conditional approval and accelerated approval from the Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA) in the future."

Commercial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Paros I-Bio “Acute Myeloid Leukemia Treatment PHI-101, Designated as Orphan Drug by the Ministry of Food and Drug Safety” [Google translation] (ET news) - "ParosiBio announced on the 4th that its relapsed and refractory acute myeloid leukemia (AML) treatment drug 'PHI-101' is scheduled to be designated as an orphan drug in the development stage by the Ministry of Food and Drug Safety (hereinafter referred to as the MFDS)....It is ParosiBio's core pipeline that completed recruitment of patients for phase 1 clinical trials in July of this year and is expected to end within the year."

Orphan drug • Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Paros I-Bio signs MTA for two new drug pipelines with Australian Childhood Cancer Research Institute [Google translation] (Hankyung) - "ParosiBio...announced on the 12th that it has signed a material transfer agreement (MTA) with Dr. David Zigler, a brain tumor researcher at the Children's Cancer Institute Australia in Sydney, Australia, to expand the indications and conduct translational research for its core pipelines, PHI-101 and PHI-501. This agreement was conducted for the purpose of verifying the efficacy of two of ParosiBio's pipelines, radiosensitizer PHI-101-RS and pan-RAF mutation inhibitor PHI-501, in patient samples derived from pediatric brain tumors, a rare disease....The Australian Childhood Cancer Institute and Dr. David Ziegler plan to study the efficacy of PHI-101-RS as a CHK2 inhibitor in diffuse intrinsic pontine glioma (DIPG), a severe pediatric disease."

Licensing / partnership • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Glioma • Oncology • Solid Tumor

Paros I-Bio, Phase 1 clinical trial for leukemia treatment begins in earnest [Google translation] (Pinpoint News) - "According to industry sources on the 1st, Paros I-Bio has completed the recruitment of patients for the multinational phase 1 clinical trial of 'PHI-101', an acute myeloid leukemia treatment targeting FLT3 mutations...This clinical trial is being conducted in Korea and Australia for patients with acute myeloid leukemia who have relapsed or are refractory to other treatments....Currently, 30 patients have been registered, and a phase 1b clinical trial is underway with the expanded recommended dose of 160 mg as a single therapy."

Enrollment status • Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

“The global market is focused on the development of AI new drugs… “We will strengthen global partnerships” Pharos iBio announces Bio USA corporate IR session [Google translation] (Pharos iBio Press Release) - "Paros iBio...announced on the 3rd that it will participate in the IR session of the '2024 Bio International Convention...Paros iBio will showcase its technology in developing treatments for rare and incurable diseases using the AI ​​new drug development platform Chemiverse, as well as major rare and incurable disease treatment pipelines PHI-101 and PHI-501...PHI-101-OC is currently undergoing phase 1 clinical trials in Korea...Paros iBio plans to complete the phase 1 clinical trial of PHI-101 this year with the goal of entering the phase 2 clinical trial of PHI-101, an acute myeloid leukemia treatment, in the United States, Australia, and Korea in 2025. Once it enters phase 2, we plan to review an early commercialization strategy by applying for conditional product approval as an orphan drug depending on the results. PHI-501, a treatment for solid tumors, will complete preclinical trials around the third quarter of this year and submit an clinical trial plan (IND)."

New P2 trial • Preclinical • Trial completion date • Trial status • Acute Myelogenous Leukemia • Gynecologic Cancers • Hematological Malignancies • Leukemia • Oncology • Ovarian Cancer • Solid Tumor

Pharos iBio expects to proceed with main clinical trials of PHI- combination therapy... [Google translation] (eDaily) - "]Pharos iBio...confirmed the effectiveness of combination therapy with its main pipeline PHI-101.Combination therapy is administered together with drugs previously used as first-line treatments, and is expected to expand to first-line treatment for AML in the future...According to Pharos Bio on the 7th, PHI-101, which is being studied as a treatment for AML, showed excellent efficacy in preclinical trials of combination therapy as well as monotherapy, increasing the likelihood of development success....Looking at the preclinical results of PHI-combination therapy, when PHI- was administered in triple combination with venetoclax and azacitidine, which are recommended as standard treatment for AML,the median survival time was days. This is days longer than the median survival time of days for the untreated control group. Additionally, compared to the median survival time of days when receiving venetoclax and azacitidine,the standard treatment recommended for AML..."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

PHI-101 synergizes with chemotherapy and venetoclax in preclinical models of acute myeloid leukemia (AACR 2024) - "Additionally, treatment of mice with low-dose PHI-101 inhibited tumor regrowth and further potentiated venetoclax or azacytidine response in vivo. Our results suggest that the combination of PHI-101 and venetoclax or azacitidine may have the advantage of improving clinical responses in FLT3-ITD AML patients and offers a potential therapeutic option to treat patients with newly diagnosed or relapsed/refractory FLT3-mutant AML."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3

Pharos iBio announces efficacy of combination therapy with targeted anticancer drug PHI-101 at AACR [Google translation] (Medifonews) - "According to the results announced by Pharos iBio, PHI-101 showed differential efficacy in both combination therapy with Venetoclax and triple combination therapy with Venetoclax and Azacitidine...PHI-101 showed a tumor growth inhibition rate (TGI) of 95% when administered in combination with venetoclax in a xenograft animal efficacy evaluation model...when PHI-501 was administered alone to animals xenografted with a BRAF (V600E) mutant melanoma cancer cell line that induced dabrafenib resistance, it showed an effect of inhibiting tumor growth by 72.1%."

Preclinical • Acute Myelogenous Leukemia • Leukemia • Melanoma • Oncology • Skin Cancer

Pharos iBio PHI-101 obtained approval for use in remission maintenance therapy [Google translation] (Medifonews) - "Pharos iBio...announced on the 28th that its acute myeloid leukemia treatment (AML) 'PHI-101' has received approval for use for remission maintenance therapy from the Ministry of Food and Drug Safety (MFDS). Asan Medical Center in Seoul applied for additional use of the drug as maintenance therapy for patients who achieved complete remission after participating in the clinical trial of PHI-101....The patient eligible for approval had recurrence of acute myeloid leukemia after hematopoietic stem cell transplantation and participated in the PHI-101 clinical trial in the first half of this year. He achieved complete remission (CR) through the administration of PHI-101 and recently underwent allogeneic hematopoietic stem cell transplantation. With this application for use approved, PHI-101 will be administered as maintenance therapy for remission."

Non-US regulatory • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Evaluation of Synergistic Anti-Leukemic Efficacy of PHI-101 in Preclinical Model of FLT3-ITD Acute Myeloid Leukemia (ASH 2023) - "Study Design and Combination effects of simultaneous versus sequential treatment of PHI-101 with other agents, including daunorubicin, cytarabine, venetoclax (Ven), and azacytidine (Aza) were tested using human leukemia cell lines harboring FLT3-ITD mutations (MV4-11, Molm13, Molm14) or FLT3-wild type as controls...The GI 50 of the gilteritinib was 5... Treatment of AML cells with the combination of Ven or Aza with PHI-101 in vitro induced rapid induction of apoptosis and inhibition of cell growth that showed significant synergy. In vivo data showed improved efficacy for the combination treatment with these agents. In vitro and in vivo data from the preclinical AML models provides a rationale to evaluate the activity of PHI-101 in combination for patients who are ineligible for more intensive chemotherapeutic induction therapy."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ANXA5 • BCL2 • FLT3

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial (ASH 2023) - P1a/1b | "Ten pts were R/R following previous treatment with other FLT3 inhibitors (gilteritinib, quizartinib, midostaurin, or HM43239). In dose-escalating phase Ia clinical trials, PHI-101 was well tolerated at all dose levels with no DLTs. Phase Ib dose-expansion trials with 160 mg daily dosing are currently ongoing. PHI-101 has delivered CRcs at 120 mg and 160 mg."

Clinical • P1 data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • FLT3

Pharos iBio announces phase 1 results for acute myeloid leukemia treatment [Google translation] (HIT News) - P1a/1b | N=42 | NCT04842370 | "Pharos iBio...participated in the American Society of Hematology (ASH) and developed an acute myeloid leukemia treatment (AML) 'PHI-101 (development code name)' announced on the 12th that it has disclosed the results of its phase 1a/b clinical trial...Phase 1b clinical trials are being conducted with 160mg monotherapy, which is the recommended expanded dose (RDE), and 60% of evaluable patients to date have shown a composite complete response. Comprehensive complete response includes complete response (CR), CR with incomplete hematological recovery (CRi), and morphological leukemia-free state (MLFS)....Paros iBio plans to complete the phase 1 clinical trial of PHI-101 in the first half of next year and begin phase 2 in the United States, Australia, and Korea in the second half of next year. We aim to complete phase 2 clinical trials of PHI-101 around 2025 and apply for conditional product approval through the 'development-stage..."

New P2 trial • P1 data • Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Janssen’s ’JNJ-42756493’ remains the most administered to cancer patients without a cure [Google translation] (News The Voice Healthcare) - "Although no medicines have been approved in the past three quarters, how many medicines have been administered to treat patients under the judgment of medical staff? According to the Ministry of Food and Drug Safety's approval status for therapeutic purposes in the third quarter... 'BYL719/Alpelisib' in two cases, PHI-101' in patients with relapsed or refractory acute myeloid leukemia...'Lazertinib’ was administered to each patient."

Commercial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Paros iBio participates in the Australian bio conference ‘OS Biotech’ [Google translation] (HIT News) - "Paros iBio...will hold a Korea-Australia pharmaceutical bio exchange at 'AusBiotech 2023', a bio industry conference held in Brisbane, Australia from the 1st to 3rd of next month (local time). They announced on the 10th that they plan to attend as a company....Paros iBio plans to seek opportunities to build global partnerships for the successful commercialization of its rare disease pipeline at OS Biotech. Representative examples include PHI-101 (acute myeloid leukemia), which is undergoing global phase 1b clinical trials, and PHI-501 (solid cancer), which is in the preclinical stage in Korea. Paros iBio was also selected as a presenting company for the 'Korean Biotech Leaping towards Innovative Technology' session during this event."

Licensing / partnership • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

Pharos iBio and Johns Hopkins partner in translational AML drug study (Korea Biomedical Review) - "Pharos iBio...said it would conduct a translational study with Johns Hopkins University School of Medicine to develop a combination therapy using its pipeline PHI-101 to treat relapsed or refractory acute myeloid leukemia (AML)...The Korean company and Donald Small, MD, Ph.D, a professor of pediatric oncology at Johns Hopkins who is a world-renowned expert in AML, will conduct the study to assess the efficacy of PHI-101 in combination with azacitidine (brand name: Vidasa) or venetoclax (brand names: Venclexta and Venclyxto), which are used as the first-line treatment of AML....'PHI-101 for AML is our flagship pipeline, and we are preparing for a global phase 2 clinical trial, including the U.S., Australia, and Korea, targeted for the first half of 2024.'"

Licensing / partnership • New P2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology